The Wuhan Institute of Virology has developed a nasal nanovaccine designed to offer broad protection against major COVID-19 variants and potential future mutations. Combining ferritin with coronavirus epitopes to trigger immune responses, this new vaccine has shown promise in early studies against strains such as Delta, Omicron, and the original Wuhan strain.